125 related articles for article (PubMed ID: 21950989)
21. The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.
Alviña K; Khodakhah K
J Neurosci; 2010 May; 30(21):7258-68. PubMed ID: 20505092
[TBL] [Abstract][Full Text] [Related]
22. Upbeat about downbeat nystagmus.
Halmagyi GM; Leigh RJ
Neurology; 2004 Aug; 63(4):606-7. PubMed ID: 15326227
[No Abstract] [Full Text] [Related]
23. RNAi silencing of P/Q-type calcium channels in Purkinje neurons of adult mouse leads to episodic ataxia type 2.
Salvi J; Bertaso F; Mausset-Bonnefont AL; Metz A; Lemmers C; Ango F; Fagni L; Lory P; Mezghrani A
Neurobiol Dis; 2014 Aug; 68():47-56. PubMed ID: 24768804
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological advances in the treatment of neuro-otological and eye movement disorders.
Strupp M; Brandt T
Curr Opin Neurol; 2006 Feb; 19(1):33-40. PubMed ID: 16415675
[TBL] [Abstract][Full Text] [Related]
25. Aberrant cerebellar Purkinje cell activity as the cause of motor attacks in a mouse model of episodic ataxia type 2.
Tara E; Vitenzon A; Hess E; Khodakhah K
Dis Model Mech; 2018 Sep; 11(9):. PubMed ID: 30279196
[TBL] [Abstract][Full Text] [Related]
26. Introducing treatment strategy for cerebellar ataxia in mutant med mice: combination of acetazolamide and 4-aminopyridine.
Abbasi S; Abbasi A; Sarbaz Y
Comput Methods Programs Biomed; 2014 Feb; 113(2):697-704. PubMed ID: 24326337
[TBL] [Abstract][Full Text] [Related]
27. Clinical use of 4-aminopyridine in patients with downbeat nystagmus.
Domínguez-Durán E; Mármol-Szombathy I; Baños-Roldán Ú; Sánchez-Gómez S
Acta Otorrinolaringol Esp (Engl Ed); 2020; 71(1):40-44. PubMed ID: 31078225
[TBL] [Abstract][Full Text] [Related]
28. Effects of dalfampridine on attacks in patients with episodic ataxia type 2: an observational study.
Claassen J; Teufel J; Kalla R; Spiegel R; Strupp M
J Neurol; 2013 Feb; 260(2):668-9. PubMed ID: 23183922
[No Abstract] [Full Text] [Related]
29. Effect of 3,4-diaminopyridine on the gravity dependence of ocular drift in downbeat nystagmus.
Helmchen C; Sprenger A; Rambold H; Sander T; Kömpf D; Straumann D
Neurology; 2004 Aug; 63(4):752-3. PubMed ID: 15326263
[No Abstract] [Full Text] [Related]
30. Beneficial effects of 3,4-diaminopyridine on positioning downbeat nystagmus in a circumscribed uvulo-nodular lesion.
Helmchen C; Gottschalk S; Sander T; Trillenberg P; Rambold H; Sprenger A
J Neurol; 2007 Aug; 254(8):1126-8. PubMed ID: 17410325
[No Abstract] [Full Text] [Related]
31. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias.
Strupp M; Kalla R; Claassen J; Adrion C; Mansmann U; Klopstock T; Freilinger T; Neugebauer H; Spiegel R; Dichgans M; Lehmann-Horn F; Jurkat-Rott K; Brandt T; Jen JC; Jahn K
Neurology; 2011 Jul; 77(3):269-75. PubMed ID: 21734179
[TBL] [Abstract][Full Text] [Related]
32. 18F-fluorodeoxyglucose hypometabolism in cerebellar tonsil and flocculus in downbeat nystagmus.
Bense S; Best C; Buchholz HG; Wiener V; Schreckenberger M; Bartenstein P; Dieterich M
Neuroreport; 2006 Apr; 17(6):599-603. PubMed ID: 16603919
[TBL] [Abstract][Full Text] [Related]
33. Treatment of the gravity dependence of downbeat nystagmus with 3,4-diaminopyridine.
Sprenger A; Rambold H; Sander T; Marti S; Weber K; Straumann D; Helmchen C
Neurology; 2006 Sep; 67(5):905-7. PubMed ID: 16966567
[TBL] [Abstract][Full Text] [Related]
34. Co-treatment with riluzole, a neuroprotective drug, ameliorates the 3-acetylpyridine-induced neurotoxicity in cerebellar Purkinje neurones of rats: behavioural and electrophysiological evidence.
Janahmadi M; Goudarzi I; Kaffashian MR; Behzadi G; Fathollahi Y; Hajizadeh S
Neurotoxicology; 2009 May; 30(3):393-402. PubMed ID: 19442824
[TBL] [Abstract][Full Text] [Related]
35. Pharmacotherapy of vestibular disorders and nystagmus.
Strupp M; Kremmyda O; Brandt T
Semin Neurol; 2013 Jul; 33(3):286-96. PubMed ID: 24057832
[TBL] [Abstract][Full Text] [Related]
36. Aminopyridines for the treatment of neurologic disorders.
Strupp M; Teufel J; Zwergal A; Schniepp R; Khodakhah K; Feil K
Neurol Clin Pract; 2017 Feb; 7(1):65-76. PubMed ID: 28243504
[TBL] [Abstract][Full Text] [Related]
37. 4-aminopyridine improves downbeat nystagmus, smooth pursuit, and VOR gain.
Kalla R; Glasauer S; Schautzer F; Lehnen N; Büttner U; Strupp M; Brandt T
Neurology; 2004 Apr; 62(7):1228-9. PubMed ID: 15079036
[No Abstract] [Full Text] [Related]
38. The first knockin mouse model of episodic ataxia type 2.
Rose SJ; Kriener LH; Heinzer AK; Fan X; Raike RS; van den Maagdenberg AM; Hess EJ
Exp Neurol; 2014 Nov; 261():553-62. PubMed ID: 25109669
[TBL] [Abstract][Full Text] [Related]
39. Episodic ataxia type 2.
Strupp M; Zwergal A; Brandt T
Neurotherapeutics; 2007 Apr; 4(2):267-73. PubMed ID: 17395137
[TBL] [Abstract][Full Text] [Related]
40. The role of small-conductance Ca2+-activated K+ channels in the modulation of 4-aminopyridine-induced burst firing in rat cerebellar Purkinje cells.
Yazdi HH; Janahmadi M; Behzadi G
Brain Res; 2007 Jul; 1156():59-66. PubMed ID: 17493598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
